Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
P01138
UPID:
NGF_HUMAN
Alternative names:
-
Alternative UPACC:
P01138; A1A4E5; Q6FHA0; Q96P60; Q9P2Q8; Q9UKL8
Background:
Beta-nerve growth factor (NGF) plays a pivotal role in the development and maintenance of the sympathetic and sensory nervous systems. It acts as an extracellular ligand for NTRK1 and NGFR receptors, initiating signaling cascades that regulate neuronal proliferation, differentiation, and survival. The precursor form of NGF, proNGF, has contrasting roles, promoting neuronal apoptosis and affecting neuronal growth cone dynamics.
Therapeutic significance:
NGF's involvement in hereditary sensory and autonomic neuropathy type 5 (HSAN5), characterized by loss of pain perception and impaired temperature sensitivity, underscores its therapeutic potential. Understanding NGF's dual roles offers insights into developing treatments for sensory and autonomic nervous system disorders.